March 26, 2026 4:55pm

Indexes and share pricings stumbled the Nasdaq which entered correction territory after oil prices spiked in the wake of war-induced commodity disruptions

More downside risk ahead …

News: The Fed’s Board of Governors urged a judge to reject prosecutors’ request that he reconsider his decision to quash subpoenas issued in a criminal investigation of Chair Jerome Powell.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening; None, waiting for what – rumors to decide share pricing

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind 

... it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Thursday: The Dow closed DOWN -469.38 points or -1.01%, the S&P closed DOWN -114.74 points or -1.74% while the Nasdaq closed DOWN -521.744 points or -2.38%

  • Theme of the session: Crude prices rose on Thursday, putting pressure on equities

Thursday’s (my) 40-company covered sector’s advance/decline line opened positive with 25 incliners, 13 decliners and 2 flats, ending with a negative close of 15 incliner, 22 decliners and 3 flats

  • Transitory as algos do their harm while helping share pricing

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • In the face of the contradictory statements made by the Iran regarding peace talks …
  • Markets “seem to be concluding that Iran’s negative public message may be a smokescreen for a more accommodating private posture”

The CBOE Fear (VIX) index, Thursday closed at 28.31, after Wednesday’s 25.40, Tuesday’s 26.94, Monday’s 26.46, Friday’s 26.78 and last Thursday’s 24.36

Metrics: Thursday …

  • The RUT was down -43.06 points or -1.70%,
  • The XLV was down -0.50 points or -0.34%,
  • The NBI was down -12.878 points or -0.22%;
  • The XBI was down -0.02 points or -0.02%
  • The IWM was down - or -%;
  • The IBB was down -0.49 points or -0.30%,
  • The VIX was up +2.98 points or +11.76% at to 28.31

 

Q1/26 – March – 8 positive and 11 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Thursday Closing UP (10 of 15) 

  • IQVIA Holdings (IQV +$3.82 after Wednesday’s -$0.43 after Tuesday’s +$0.74 after Monday’s +$0.93),
  • Ionis Pharmaceuticals (IONS +$1.54 after Wednesday’s +$3.01 after Tuesday’s -$1.11 after Monday’s -$0.20),
  • Precigen (PGEN +$0.80 after Wednesday’s -$0.03),
  • Supernus Therapeutics (SUPN +$0.73),
  • Beam Therapeutics (BEAM +$0.50 after Wednesday’s -$0.83 after Tuesday’s -$1.22 after Monday’s +$0.54),
  • Solid Biosciences (SLDB +$0.50),
  • CRISPR Therapeutics CRSP +$0.46),
  • Entrada Therapeutics (TRDA +$0.26),
  • Ultragenyx Pharmaceuticals (RARE +$0.15 after Wednesday’s +$1.35 after Tuesday’s -$1.77 after Monday’s +$0.40)
  • Voyager Therapeutics (VYGR +0.10)

Flat (3)

  • Arrowhead Pharmaceuticals (ARWR $0.00 after Wednesday’s +$4.50),
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Generation Bio (GBIO) – acquired

Thursday’s Closing DOWN (10 of 22): 

  • Wave Life Sciences (WVE -$6.10),
  • Sarepta Therapeutics (SRPT -$2.09 after Wednesday’s +$6.16),
  • BioNTech (BNTX -$1.31 after Wednesday’s +$1.96 after Tuesday’s -$1.60 after Monday’s -$0.86),
  • Vertex (VRTX -$1.23 after Wednesday’s +$6.35 after Tuesday’s -$2.61 after Monday’s +$2.85),
  • AxoGen (AXGN -$1.03),
  • Mesoblast (MESO -$0.79 after Wednesday’s +$1.33 after Tuesday’s +$0.30 after Monday’s -$0.34),
  • uniQure NV (QURE -$0.76 after Wednesday’s +$1.18 after Tuesday’s -$0.74),
  • Vericel (VCEL -$0.62 after Wednesday’s -$1.64 after Tuesday’s +$0.63),
  • Alnylam Pharmaceuticals (ALNY -$0.54 after Wednesday’s +$20.65 after Tuesday’s +$1.39 after Monday’s -$5.51),
  • Dyne Therapeutics (DYN -$0.43),

 

The Bottom Line: More of the … WHY

US stocks accelerated losses on Thursday, with tech and semiconductor stocks leading the market sell-off.

  • Conflicting messages from the US and Iran fueled mounting uncertainty over the Middle East conflict as oil hovered above $100.
  • Oil prices jumped, with Brent crude futures holding firmly above $102. West Texas Intermediate crude moved above $94 before slightly pulling back.

Investors went risk-off during the session, as stocks sank while bond yields rose.

  • The 10-year Treasury yield rose to 4.42% on Thursday.

For the week:

  • The S&P 500 is down 29.32 points, or 0.5%.
  • The Dow is up 382.64 points, or 0.8%.
  • The Nasdaq is down 239.53 points, or 1.1%.
  • The Russell 2000 is up 54.87 points, or 2.3%.

 

March – 4th week:

  • 3/26 – Thursday closed negative with 15 incliner, 22 decliners and 3 flats
  • 3/25 – Wednesday closed positive with 30 incliners, 5 decliners and 5 flats
  • 3/24 – Tuesday closed negative with 11 incliner, 27 decliners and 2 flats
  • 3/23 - Monday closed positive with 26 incliners, 12 decliners and 2 flats

March – 3rd week

  • 3/20 – Friday closed negative with 6 incliner, 33 decliners and 1 flat
  • 3/19 – Thursday closed positive with 20 incliners, 18 decliners and 2 flats
  • 3/18 – Wednesday closed negative with 3 incliner, 35 decliners and 2 flats
  • 3/17 - Tuesday closed positive with 25 incliners, 14 decliners and 1 flat
  • 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: IQIA Holdings (IQV), Ionis Pharmaceuticals IONS) and Precigen (PGEN)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and Vericel (VCEL)
  • Monday: IQIA Holdings (IQV), Vericel (VCEL) and CRISPR Therapeutics (CRSP)

The worst three (3) in the session: Losers

  • Thursday: Wave Life Sciences (WVE), Sarepta Therapeutics (SRPT) and BioNTech (BNTX)
  • Wednesday: Vericel (VCEL), IQVA Holdings (IQV) and Beam Therapeutics (BEAM)
  • Tuesday: Lenz therapeutics (LENZ), Ultragenyx Pharmaceuticals (RARE) and Vertex (VRTX)
  • Monday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Wave Life Sciences (WVE)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.